Table 1.
Demographic, Genetic, and Clinical Characteristics of Participants
| DEMOGRAPHIC VARIABLES | N = 495 |
| Age, mean (SD), years | 55 (13) |
| Gender | |
| female, n (%) | 234 (47%) |
| male, n (%) | 261 (53%) |
| Race | |
| Caucasian, n (%) | 434 (88%) |
| African-American, n (%) | 47 (9%) |
| Other, n (%) | 14 (3%) |
| Hispanic ethnicity, n (%) | 6 (1%) |
| GENETIC VARIABLES | |
| VKORC1 A haplotypea frequency | 37.5% |
| CYP2C9*2 allele frequency | 12.2% |
| CYP2C9*3 allele frequency | 6.4% |
| CLINICAL VARIABLES | |
| geometric mean warfarin dose, mg/day, (SD) |
4.4 (1.5) |
| body surface area, in m2 mean (SD) | 2.05 (0.27) |
| smoker, n (%) | 57 (12%) |
| takes statin, n (%) | 53 (11%) |
| takes amiodarone, n (%) | 0 (0%) |
| takes aspirin, n (%) | 97 (20%) |
SD = standard deviation; VKORC1 = vitamin K epoxide reductase complex 1. CYP = cytochrome P 450.
a
The VKORC1 A haplotype can be detected by −1639 G>A;